H.R. 10150: Advancing Botanical Drug Development Act of 2026

This bill would create a special 12-year market exclusivity period for certain FDA-approved botanical drugs that are approved through a new drug application submitted after the bill becomes law.

What that means

• If a botanical drug is approved under the FDA’s standard new drug approval process, then for 12 years the FDA could not let a generic or other follow-on application referencing that drug become effective.
• This does not change the safety or effectiveness standards for approval. Botanical drugs would still need to meet the FDA’s normal requirements.
• The bill defines a botanical drug as one that is treated as a botanical drug under the FD&C Act, as determined by the Secretary through regulation.

Purpose described in the bill

The bill says botanical drugs can be harder and more expensive to develop than conventional drugs because plant-based ingredients can vary and require extra work to ensure consistent quality, safety, and effectiveness. It states that existing patent and exclusivity protections may not be enough to attract investment in this area, and that giving longer exclusivity could encourage more research and development of botanical treatments.

Practical effect

For companies that develop approved botanical drugs, the bill would provide a longer period of protection from direct FDA- अनुमाधित competition. That could give those products more time on the market without generic or similar follow-on versions. For patients and health care providers, the main effect would be on when lower-cost competing versions of those products could potentially become available.

Relevant Companies

None found